RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is RenovoGem, an oncology drug-device combination product, consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. The company has a research collaboration with Imugene Limited to deliver oncolytic virus therapy for the treatment of difficult-to-access tumors. RenovoRx, Inc. was founded in 2009 and is headquartered in Los Altos, California.
| 1.2885 | |
| 1.28 | |
| - | |
| 1.295 | |
| 1.1834 | |
| 0.531-2.35 | |
| 29 461 K | |
| 23 952 K | |
| 0 | |
| -0.07 | |
| 1.008 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
Collaboration will explore trans-arterial delivery of Imugene’s CF33 oncolytic virus utilizing RenovoRx’s TAMP therapy platform. TAMP is expected to enable localized, targeted delivery of CF33 to ...
Toward the end of trading Wednesday, the Dow traded down 0.67% to 36,075.12 while the NASDAQ fell 1.90% to 15,585.20. The S&P also fell, dropping 0.99% to 4,638.64. The U.S. has the highest number of...
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
